Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance.

Boston Scientific (BSX) Didn’t Miss on Demand or Devices. A Cyberattack Just Broke Its Guidance.

Venkatesh Srinivasalu

Sun, September 13, 2026 at 10:31 PM GMT+3 3 min read

• BSX -0.28%

Boston Scientific Corporation (NYSE:BSX) fell 2.3% in early trading on September 8, 2026, after disclosing that an August 25 cyberattack disrupted manufacturing and shipping. The company stated it is unlikely to meet its previously issued third-quarter and full-year 2026 guidance for net sales and adjusted earnings per share. Though operations have since resumed, the incident is expected to weigh on third-quarter and full-year results. The risk that never gets modelled by Wall Street has just sent one of medtech's best compounders off course.

Not Demand, Not Devices — Downtime

Farapulse, Boston Scientific's pulsed-field-ablation system, still commands a major share of the US atrial-fibrillation market. The incident itself does not appear to reflect a product-quality problem. The lost sales are orders that could not ship. The demand still exists, and the distribution is already back online. It increases the chances of recovery from a stumble. However, Farapulse was already facing competitive pressure before the cyberattack. Boston Scientific had projected flat global electrophysiology growth for the second half of 2026 after lowering its market-share assumptions, so the outage adds another near-term complication rather than causing the existing EP slowdown

The Bear Case Is More Than "Hackers Happen"

Three structural risks complicate the company's recovery. First, a disruption large enough to impair manufacturing and order fulfillment exposes an operational vulnerability that investors may not have fully priced. Second, the warning that Boston Scientific is unlikely to meet its previously issued guidance further resets near-term earnings expectations. Third, the gap between the initial August 25 disclosure and the September 8 financial warning highlights how difficult the ultimate impact was to quantify. Additionally, in a rapidly adopting PFA market, there also exists the subtlest risk of customer retention. Temporary shipping disruption can hand procedures to Medtronic and Johnson & Johnson that may not fully come back.

Hedge Fund Positioning

Institutional positioning had already begun to ease before the disclosure. Insider Monkey records 99 hedge funds holding BSX shares in the second quarter of 2026, down from 106 in the prior quarter. Short interest remains low at 1.9% of the float, indicating that the current selling reflects portfolio adjustments rather than coordinated short positioning.

Bottom Line

The franchise is intact, and the cause behind the guidance cut is exogenous, making Boston Scientific Corporation (NYSE:BSX) one of the better recovery candidates. For investors who remain constructive on the long-term PFA franchise, the selloff could create a recovery setup, but near-term visibility remains unusually weak. However, realized operational risks often lead to valuation multiple compression. Wait for the third-quarter results. A stronger entry case would depend on stabilized order rates and evidence that electrophysiology market share remains intact.

While we acknowledge the potential of BSX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on thebest short-term AI stock.

READ NEXT: Spyre (SYRE) Fell 13% on Its Weakest Program. Its Best One Just Worked and The PayPal (PYPL) Buyout Is No More. Now Investors Have to Decide if the Business Is Worth It.

Disclosure: None. Follow Insider Monkey on Google News.